{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:45:35Z","timestamp":1791499535456,"version":"4.3.4"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T00:00:00Z","timestamp":1648684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Vet. Sci."],"abstract":"<jats:p>The aim of this study was to evaluate the efficacy of metronomic chemotherapy in the palliative treatment of various malignant oral tumors in dogs. Our focus was to determine the effect of treatment on local disease control and to assess the tolerability and safety of the treatment in dogs with various oral malignancies. Metronomic chemotherapy with cyclophosphamide was used to treat 12 dogs and was combined with non-steroidal anti-inflammatory drugs in 6\/12 (50%) of dogs. A clinical benefit was observed in 6\/12 (50%) patients 1 month and in 4\/12 (33%) 3 months after treatment initiation. The median survival time of the dogs was 155 days (range 21\u2013529 days). At the end of the observation period, the disease had progressed in 10\/12 (83.3%) of the patients. Sterile hemorrhagic cystitis was the most commonly reported side effect of treatment, occurring in 4\/12 (33.3%) dogs. The results of our study suggest that metronomic chemotherapy with cyclophosphamide can be, in a subset of dogs, beneficial in the palliation of malignant oral tumors.<\/jats:p>","DOI":"10.3389\/fvets.2022.856399","type":"journal-article","created":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:33:58Z","timestamp":1648726438000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Metronomic Chemotherapy for Palliative Treatment of Malignant Oral Tumors in Dogs"],"prefix":"10.3389","volume":"9","author":[{"given":"Nina","family":"Milevoj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Nemec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nata\u0161a","family":"Tozon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,3,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/nrc1369","article-title":"The anti-angiogenic basis of metronomic chemotherapy","volume":"4","author":"Kerbel","year":"2004","journal-title":"Nat Rev Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1172\/JCI9872","article-title":"Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice","volume":"105","author":"Hanahan","year":"2000","journal-title":"J Clin Invest."},{"key":"B3","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1939-1676.2011.00883.x","article-title":"Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer","volume":"26","author":"Mitchell","year":"2012","journal-title":"J Vet Intern Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","article-title":"Low dose cyclophosphamide: mechanisms of T cell modulation","volume":"42","author":"Madondo","year":"2016","journal-title":"Cancer Treat Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.critrevonc.2011.04.009","article-title":"Cyclophosphamide-based metronomic chemotherapy: after 10 years of experience, where do we stand and where are we going?","volume":"82","author":"Penel","year":"2012","journal-title":"Crit Rev Oncol Hematol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.ccr.2006.11.020","article-title":"A perivascular niche for brain tumor stem cells","volume":"11","author":"Calabrese","year":"2007","journal-title":"Cancer Cell."},{"key":"B7","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1158\/0008-5472.CAN-06-4238","article-title":"Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors","volume":"67","author":"Folkins","year":"2007","journal-title":"Cancer Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1038\/labinvest.2012.65","article-title":"Residual dormant cancer stem-cell foci are responsible for tumor relapse after antiangiogenic metronomic therapy in hepatocellular carcinoma xenografts","volume":"92","author":"Martin-Padura","year":"2012","journal-title":"Lab Investig."},{"key":"B9","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1038\/nrclinonc.2014.89","article-title":"Metronomics: towards personalized chemotherapy?","volume":"11","author":"Andr\u00e9","year":"2014","journal-title":"Nat Rev Clin Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1038\/nrclinonc.2010.82","article-title":"Metronomic chemotherapy: new rationale for new directions","volume":"7","author":"Pasquier","year":"2010","journal-title":"Nat Rev Clin Oncol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1111\/j.1939-1676.2011.0753.x","article-title":"Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma","volume":"25","author":"Burton","year":"2011","journal-title":"J Vet Intern Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1007\/s10637-011-9672-y","article-title":"First-line metronomic chemotherapy in a metastatic model of spontaneous canine tumours: a pilot study","volume":"30","author":"Marchetti","year":"2012","journal-title":"Invest New Drugs."},{"key":"B13","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/j.1476-5829.2011.00280.x","article-title":"Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer","volume":"10","author":"Leach","year":"2012","journal-title":"Vet Comp Oncol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1111\/vco.12179","article-title":"Phase I lead-in and subsequent randomized trial assessing safety and modulation of regulatory T cell numbers following a maximally tolerated dose doxorubicin and metronomic dose cyclophosphamide combination chemotherapy protocol in tumour-bearing dogs","volume":"15","author":"Rasmussen","year":"2017","journal-title":"Vet Comp Oncol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/j.1939-1676.2007.tb03019.x","article-title":"Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs","volume":"21","author":"Lana","year":"2007","journal-title":"J Vet Intern Med."},{"key":"B16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.2460\/javma.247.4.393","article-title":"Survival time of dogs with splenic hemangiosarcoma treated by splenectomy with or without adjuvant chemotherapy: 208 cases (2001\u20132012)","volume":"247","author":"Wendelburg","year":"2015","journal-title":"J Am Vet Med Assoc."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1111\/j.1939-1676.2008.0179.x","article-title":"Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas","volume":"22","author":"Elmslie","year":"2008","journal-title":"J Vet Intern Med."},{"key":"B18","first-page":"51","article-title":"Evaluation of toxicity of a chronic alternate day metronomic cyclophosphamide chemotherapy protocol in dogs with naturally occurring cancer","volume":"58","author":"Matsuyama","year":"2017","journal-title":"Can Vet J."},{"key":"B19","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/vco.12393","article-title":"Survival analysis of dogs with advanced primary lung carcinoma treated by metronomic cyclophosphamide, piroxicam and thalidomide","volume":"16","author":"Polton","year":"2018","journal-title":"Vet Comp Oncol."},{"key":"B20","doi-asserted-by":"publisher","first-page":"304","DOI":"10.5326\/JAAHA-MS-6540","article-title":"Adjuvant doxorubicin with or without metronomic cyclophosphamide for canine splenic hemangiosarcoma","volume":"53","author":"Matsuyama","year":"2017","journal-title":"J Am Anim Hosp Assoc."},{"key":"B21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.1939-1676.2011.0684.x","article-title":"Tolerability of metronomic administration of lomustine in dogs with cancer","volume":"25","author":"Tripp","year":"2011","journal-title":"J Vet Intern Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.2460\/javma.242.11.1534","article-title":"Metronomic administration of chlorambucil for treatment of dogs with urinary bladder transitional cell carcinoma","volume":"242","author":"Schrempp","year":"2013","journal-title":"J Am Vet Med Assoc."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.2460\/javma.252.11.1377","article-title":"Evaluation of metronomic cyclophosphamide chemotherapy as maintenance treatment for dogs with appendicular osteosarcoma following limb amputation and carboplatin chemotherapy","volume":"252","author":"Matsuyama","year":"2018","journal-title":"J Am Vet Med Assoc."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/vco.12292","article-title":"Furosemide for prevention of cyclophosphamide-associated sterile haemorrhagic cystitis in dogs receiving metronomic low-dose oral cyclophosphamide","volume":"15","author":"Setyo","year":"2017","journal-title":"Vet Comp Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1111\/jsap.12624","article-title":"Outcome and prognostic factors following curative-intent surgery for oral tumours in dogs: 234 cases (2004 to 2014)","volume":"58","author":"Sarowitz","year":"2017","journal-title":"J Small Anim Pract."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fvets.2019.00090","article-title":"Imaging in non-neurologic oncologic treatment planning of the head and neck","volume":"6","author":"Hansen","year":"2019","journal-title":"Front Vet Sci."},{"key":"B27","doi-asserted-by":"publisher","first-page":"575911","DOI":"10.3389\/fvets.2020.575911","article-title":"Electroporation-based treatments in small animal veterinary oral and maxillofacial oncology","volume":"7","author":"Nemec","year":"2020","journal-title":"Front Vet Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1111\/vco.12059","article-title":"Effects of low-dose cyclophosphamide with piroxicam on tumour neovascularization in a canine oral malignant melanoma-xenografted mouse model","volume":"13","author":"Choisunirachon","year":"2015","journal-title":"Vet Comp Oncol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3332\/ecancer.2021.1287","article-title":"Exceptional response to oral metronomic chemotherapy in a rare case of sinonasal mucosal melanoma","volume":"15","author":"Karn","year":"2021","journal-title":"Ecancermedicalscience."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e6518","DOI":"10.1097\/MD.0000000000006518","article-title":"Metronomic oral cyclosphosphamide as third-line systemic treatment or beyond in patients with inoperable locoregionally advanced recurrent or metastatic nasopharyngeal carcinoma","volume":"96","author":"Lee","year":"2017","journal-title":"Medicine."},{"key":"B31","doi-asserted-by":"publisher","first-page":"696","DOI":"10.2460\/javma.243.5.696","article-title":"Risk factors associated with survival in dogs with nontonsillar oral squamous cell carcinoma 31 cases (1990\u20132010)","volume":"243","author":"Fulton","year":"2013","journal-title":"J Am Vet Med Assoc."},{"key":"B32","first-page":"23","article-title":"\u201cClinical stages (TNM) of canine\/feline tumours of the oral cavity","volume-title":"TNM Classification of Tumours in Domestic Animals","author":"Owen","year":"1980"},{"key":"B33","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1111\/vco.12032","article-title":"Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus document","volume":"13","author":"Nguyen","year":"2015","journal-title":"Vet Comp Oncol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/vco.283","volume":"14","year":"2016","journal-title":"Vet Comp Oncol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e70","DOI":"10.4142\/jvs.2020.21.e70","article-title":"Demographics of dogs and cats with oral tumors presenting to teaching hospitals: 1996\u20132017","volume":"21","author":"Cray","year":"2020","journal-title":"J Vet Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.2460\/javma.247.10.1146","article-title":"Outcomes of dogs undergoing radiotherapy for treatment of oral malignant melanoma: 111 cases (2006\u20132012)","volume":"247","author":"Kawabe","year":"2015","journal-title":"J Am Vet Med Assoc."},{"key":"B37","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1111\/j.1748-5827.2009.00755.x","article-title":"Assessment of companion animal quality of life in veterinary practice and research","volume":"50","author":"Yeates","year":"2009","journal-title":"J Small Anim Pract."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1111\/vco.12309","article-title":"The use of low-dose metronomic chemotherapy in dogs\u2014insight into a modern cancer field","volume":"16","author":"Gaspar","year":"2018","journal-title":"Vet Comp Oncol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/jsap.12228","article-title":"Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma","volume":"55","author":"Bracha","year":"2014","journal-title":"J Small Anim Pract."},{"key":"B40","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1038\/nbt0906-1065b","article-title":"The dog as a cancer model","volume":"24","author":"Khanna","year":"2006","journal-title":"Nat Biotechnol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1111\/vco.12519","article-title":"Adjuvant anthracycline-based vs metronomic chemotherapy vs no medical treatment for dogs with metastatic splenic hemangiosarcoma: a multi-institutional retrospective study of the Italian Society of Veterinary Oncology","volume":"17","author":"Marconato","year":"2019","journal-title":"Vet Comp Oncol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/jsap.12926","article-title":"The addition of metronomic chemotherapy does not improve outcome for canine splenic haemangiosarcoma","volume":"60","author":"Alexander","year":"2019","journal-title":"J Small Anim Pract."},{"key":"B43","doi-asserted-by":"publisher","first-page":"75","DOI":"10.5326\/0440075","article-title":"Survival data for canine oral extramedullary plasmacytomas: a retrospective analysis (1996\u20132006)","volume":"44","author":"Wright","year":"2008","journal-title":"J Am Anim Hosp Assoc."},{"key":"B44","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1111\/jvim.14729","article-title":"Canine cutaneous plasmacytosis: 21 cases (2005\u20132015)","volume":"31","author":"Boostrom","year":"2017","journal-title":"J Vet Intern Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.2460\/javma.249.12.1408","article-title":"Incidence of sterile hemorrhagic cystitis in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide: 55 cases (2009\u20132015)","volume":"249","author":"Chan","year":"2016","journal-title":"J Am Vet Med Assoc."},{"key":"B46","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1111\/jsap.12635","article-title":"Toxicity of metronomic cyclophosphamide chemotherapy in a UK population of cancer-bearing dogs: a retrospective study","volume":"58","author":"Harper","year":"2017","journal-title":"J Small Anim Pract."},{"key":"B47","doi-asserted-by":"publisher","first-page":"122","DOI":"10.3322\/caac.21389","article-title":"Head and Neck cancers-major changes in the American Joint Committee on cancer eighth edition cancer staging manual","volume":"67","author":"Lydiatt","year":"2017","journal-title":"CA Cancer J Clin."},{"key":"B48","doi-asserted-by":"publisher","first-page":"506","DOI":"10.3389\/fvets.2020.00506","article-title":"Variability in recommendations for cervical lymph node pathology for staging of canine oral neoplasia: a survey study","volume":"7","author":"Congiusta","year":"2020","journal-title":"Front Vet Sci."}],"container-title":["Frontiers in Veterinary Science"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.856399\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T11:34:02Z","timestamp":1648726442000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fvets.2022.856399\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,31]]},"references-count":48,"alternative-id":["10.3389\/fvets.2022.856399"],"URL":"https:\/\/doi.org\/10.3389\/fvets.2022.856399","relation":{},"ISSN":["2297-1769"],"issn-type":[{"value":"2297-1769","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,31]]},"article-number":"856399"}}